Literature DB >> 11124853

Glucagon-like peptide-1: a major regulator of pancreatic beta-cell function.

R Perfetti1, P Merkel.   

Abstract

Glucagon-like peptide-1 (GLP-1) is a gut hormone synthesized by post-translational processing in intestinal L-cells, and it is released in response to food ingestion. GLP-1 stimulates insulin secretion during hyperglycemia, suppresses glucagon secretion, stimulates (pro)-insulin biosynthesis and decreases the rate of gastric emptying and acid secretion. GLP-1 has also been shown to have a pro-satiety effect. In addition, it has been demonstrated that a long-term infusion with GLP-1, or exendin-4, a long-acting analog of human GLP-1, increases beta-cell mass in rats. In conclusion, GLP-1 appears to regulate plasma glucose levels via various and independent mechanisms. GLP-1 is an excellent candidate option for the treatment of patients with type 2 diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124853     DOI: 10.1530/eje.0.1430717

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  33 in total

Review 1.  Developmental aspects of the endocrine pancreas.

Authors:  Daniel M Kemp; Melissa K Thomas; Joel F Habener
Journal:  Rev Endocr Metab Disord       Date:  2003-03       Impact factor: 6.514

Review 2.  The role of incretin therapy at different stages of diabetes.

Authors:  Simona Cernea
Journal:  Rev Diabet Stud       Date:  2011-11-10

Review 3.  Regulation of β-cell function by RNA-binding proteins.

Authors:  Maria Grazia Magro; Michele Solimena
Journal:  Mol Metab       Date:  2013-09-25       Impact factor: 7.422

Review 4.  GLP-1 agonist therapy for advanced heart failure with reduced ejection fraction: design and rationale for the functional impact of GLP-1 for heart failure treatment study.

Authors:  Kenneth B Margulies; Kevin J Anstrom; Adrian F Hernandez; Margaret M Redfield; Monica R Shah; Eugene Braunwald; Thomas P Cappola
Journal:  Circ Heart Fail       Date:  2014-07       Impact factor: 8.790

5.  Construction of a dietary-cure Saccharomyces cerevisiae expressing long-acting glucagon-like peptide-1 and investigation of its hypoglycemic activity in type 2 diabetes mellitus mouse model.

Authors:  Pingzhe Jiang; Chao Ma; Junfeng Hao; Yike Han; Minggang Li
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

Review 6.  Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects.

Authors:  Matthew R Hayes
Journal:  Physiol Behav       Date:  2012-02-17

7.  Incretins and amylin: neuroendocrine communication between the gut, pancreas, and brain in control of food intake and blood glucose.

Authors:  Matthew R Hayes; Elizabeth G Mietlicki-Baase; Scott E Kanoski; Bart C De Jonghe
Journal:  Annu Rev Nutr       Date:  2014-04-10       Impact factor: 11.848

8.  Development of a reliable automated screening system to identify small molecules and biologics that promote human β-cell regeneration.

Authors:  Kristie I Aamodt; Radhika Aramandla; Judy J Brown; Nathalie Fiaschi-Taesch; Peng Wang; Andrew F Stewart; Marcela Brissova; Alvin C Powers
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-09-13       Impact factor: 4.310

9.  Racial differences in glucagon-like peptide-1 (GLP-1) concentrations and insulin dynamics during oral glucose tolerance test in obese subjects.

Authors:  P A Velasquez-Mieyer; P A Cowan; G E Umpierrez; R H Lustig; A K Cashion; G A Burghen
Journal:  Int J Obes Relat Metab Disord       Date:  2003-11

10.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.